Key clinical point: Continuous or extended cycle combined oral contraceptive (COC) use was associated with a slightly elevated, but not statistically significant, risk of venous thromboembolism.
Major finding: The adjusted hazard ratio for women taking continuous/extended COCs was 1.32 (95% confidence interval, 1.07-1.74), compared with women taking noncyclic COCs, but the absolute risk difference between the two groups was low (0.27 per 1,000 persons).
Study details: A retrospective cohort study of 210,691 women with continuous/extended COC use and 522,316 women with cyclic COC use.
Disclosures: The Sentinel Initiative is funded by a contract from the Department of Health and Human Services. The authors reported no relevant conflicts of interest.
Li J et al. JAMA Intern Med. 2018 Oct 1. doi:10.1001/jamainternmed.2018.4251
This Week's Must Reads
Trends in LDL-C and 2013 Treatment Guidelines, Clin Cardiol; ePub 2018 Nov 15; Superko, et al
PCSK9 Inhibitors Reduce Risk of CV Events, Nat Rev Cardiol; ePub 2018 Nov 12; Sabatine, et al
Risk Factors for CVD in Heterozygous FH, J Clin Lipidol; ePub 2018 Nov 7; Akioyamen, et al
Hypercholesterolemia Patients on Suboptimal Statins, J Atheroscler Thromb; ePub 2018 Oct 26; Kajinami, et al
Cholesterol Guidelines Stress Lifetime Approach, Circulation; ePub 2018 Nov 10; Grundy, et al
Must Reads in Thrombosis
VTE risk for continuous cycle oral contraceptives, Li J et al. JAMA Intern Med. 2018 Oct 1. doi:10.1001/jamainternmed.2018.4251
Efficacy of NOACs in Patients with AF and VHD, J Am Heart Assoc; ePub 2018 Apr 5; Briasoulis, et al
FDA Approves Xarelto for Extended Treatment of VTE, Bayer news release; ePub 2017 Oct 30
FDA Approves Bevyxxa for Prophylaxis of VTE, FDA news release; 2017 Jun 23
Systolic BP Within 24 Hours After Thrombectomy, J Am Heart Assoc; ePub 2017 May 18; Mistry, et al